Moderna Therapeutics, Inc. announced it is now a clinical stage company with its first Phase I study for mRNA 1440 currently underway in Europe. Moderna also announced it has filed an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA) for mRNA 1851, its second clinical program, with a Phase I study anticipated to begin in first quarter 2016. mRNA 1440 and mRNA 1851 are infectious disease vaccines for undisclosed targets and indications.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
124.1 USD | -0.87% |
|
+5.63% | +24.74% |
17/07 | EU court criticizes Commission over handling of COVID vaccine contracts | RE |
15/07 | Moderna Insider Sold Shares Worth $1,756,177, According to a Recent SEC Filing | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.74% | 4.8TCr | |
-0.47% | 4.24TCr | |
+43.96% | 4.15TCr | |
+25.40% | 3.16TCr | |
+17.96% | 2.86TCr | |
-4.47% | 2.8TCr | |
+50.73% | 1.46TCr | |
+42.56% | 1.41TCr | |
+1.46% | 1.26TCr | |
-5.60% | 1.17TCr |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Moderna Therapeutics, Inc. Files an Investigational New Drug Application with the U.S. Food and Drug Administration